Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage - TopicsExpress



          

Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that preliminary efficacy in an animal model of Macrophage Activation Syndrome (MAS) has been demonstrated with its SGX94 innate defense regulator (IDR) technology, significantly mitigating the pancytopenia characteristic of MAS.
Posted on: Mon, 05 Jan 2015 15:33:58 +0000

Trending Topics



Recently Viewed Topics




© 2015